I

    Immatics NV (IMTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.53
    +0.08 (+0.85%)

    Market Cap: $1.44B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    42%(11/26)
    Avg Surprise
    -9.64%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.50
    Range$-0.54 - $-0.44
    7 analysts
    EPS RevisionsNo revisions (7d)
    4
    4
    30d
    EPS Estimate Drift
    90d ago$-0.50+1.2%
    60d ago$-0.50+1.3%
    30d ago$-0.50+1.3%
    7d ago$-0.51-1.7%
    Current$-0.50
    Revenue Consensus
    $13M
    Range$7M - $17M
    8 analysts
    Dec 31, 2026
    EPS Consensus$-0.65
    Range$-0.93 - $-0.49
    7 analysts
    Revenue Consensus
    $11M
    Range$-6856560 - $26M
    8 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.65---
    Sep 26EST
    		-$-0.50---
    Jun 26
    		$-0.53$-0.43-23.26%Miss+22.1%
    Mar 26
    		$-0.51$-0.44-15.91%Miss-37.8%
    Dec 25
    		$-0.34$-0.41+18.05%Beat-174.5%
    Sep 25
    		$-0.49$-0.45-8.89%Miss-512.5%
    Jun 25
    		$-0.68$-0.36-88.89%Miss-257.9%
    Mar 25
    		$-0.37$-0.33-12.12%Miss-1133.3%
    Dec 24
    		$0.45$-0.34+234.34%Beat+251.0%
    Sep 24
    		$-0.08N/A+71.43%Beat+76.5%
    Jun 24
    		$-0.19$-0.31+38.71%Beat+45.7%
    Mar 24
    		$-0.03N/A+86.36%Beat+89.3%
    Dec 23
    		$-0.30$-0.32+6.25%Beat-30.4%
    Sep 23
    		$-0.34$-0.39+12.82%Beat-3.0%
    Jun 23
    		$-0.35$-0.27-29.63%Miss-59.1%
    Mar 23
    		$-0.28$-0.30+6.67%Beat-119.3%
    Dec 22
    		$-0.23$-0.17-35.29%Miss+11.5%
    Sep 22
    		$-0.33$-0.44+25.00%Beat+32.7%
    Jun 22
    		$-0.22$-0.06-266.67%Miss+51.1%
    Mar 22
    		$1.45$1.92-24.48%Miss+453.7%
    Dec 21
    		$-0.26$0.20-230.00%Miss+44.7%
    Sep 21
    		$-0.49$-0.34-44.12%Miss-4.3%
    Jun 21
    		$-0.45$-0.39-15.38%Miss-87.5%
    Mar 21
    		$-0.41$-0.40-2.50%Miss-127.8%
    Dec 20
    		$-0.47N/A+61.48%Beat-2450.0%
    Sep 20
    		$-0.47$-0.29-62.07%Miss-1666.7%
    Jun 20
    		$-0.24$-0.16-50.00%Miss-580.0%
    Mar 20
    		$-0.18N/A+97.48%Beat-550.0%
    Dec 19
    		$0.02$0.00N/ABeat-
    Sep 19
    		$0.03$0.00N/ABeat-
    Jun 19
    		$0.05$0.00N/ABeat-
    Mar 19
    		$0.04$0.00N/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-4.56EV/EBITDA7.19x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-735.00%
    ROE-47.80%ROIC5.52%
    Financial Health
    Debt/Equity0.01xInterest Coverage25.09x
    Current Ratio7.54xQuick Ratio7.54x
    Trading Statistics
    Beta1.32Avg Volume562.92K
    52-Week High$12.4152-Week Low$5.05

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$9.15
    SMA 20$9.36
    SMA 50$9.44
    SMA 200$10.03
    EMA 10$9.30
    EMA 20$9.29
    EMA 50$9.47
    EMA 200$9.44

    MACD

    Line: -0.03Signal: -0.07Hist: 0.05

    ADX

    ADX: 12.0+DI: 23.5-DI: 19.5

    Aroon & PSAR

    Aroon Up52.0
    Aroon Down4.0
    PSAR$8.43

    Bollinger Bands

    Upper Band$10.03
    Lower Band$8.69
    %B Position1442%(Upper)
    Band Width0.63

    RSI (14-Day)

    Neutral
    53.5

    Momentum Oscillators

    Stoch %K66.2
    Stoch %D63.4
    Williams %R-28.5
    ROC (10d)3.0%
    Momentum0.28
    CCI (20d)19.0
    MFI (14d)46.4

    Volatility Measures

    ATR (14d)$0.49(5.1%)
    StdDev (20d)0.34
    Hist Vol50.9%(High)

    Volume Flow

    VWAP$9.44
    OBV11.5M
    AD Line2.3M
    CMF (20d)0.022

    Volume Metrics

    Avg Vol (20d)578.2K
    Vol Ratio1.2x
    VWMA (20d)$9.32

    Pivot Points

    R3$10.36
    R2$10.12
    R1$9.79
    Pivot Point$9.55
    S1$9.22
    S2$8.98
    S3$8.65

    Advanced Oscillators

    TSI-1.65
    Ultimate Osc54.1
    KST-18.72

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$9.14M$7.61M$19.76M$5.19M$4.74M$18.58M$56.25M$50.56M$18.75M$30.45M$15.92M$5.93M
    Cost of RevenueN/AN/AN/AN/AN/AN/AN/A$38.91M$94,860$32.11M$33.27M$30.50M
    Gross Profit$9.14M$7.61M$19.76M$5.19M$4.74M$18.58M$56.25M$50.56M$18.66M$-1,660,823$-17,346,000$-24,572,000
    Operating Expenses$76.35M$73.68M$58.64M$59.82M$57.86M$53.96M$55.35M$50.05M$45.32M$40.98M$43.63M$39.19M
    R&D$62.41M$59.19M$49.64M$47.18M$45.11M$41.91M$41.85M$38.91M$35.22M$32.30M$33.27M$30.50M
    SG&A$13.94M$14.51M$13.66M$12.67M$12.78M$12.07M$13.52M$11.16M$10.13M$11.64M$10.37M$8.88M
    Operating Income$-67,204,000$-66,064,000$-38,881,000$-54,633,000$-53,127,000$-35,374,000$903,000$514,000$-26,564,000$-13,560,352$-27,714,000$-33,267,000
    Interest Income$0$3.58M$3.55M$3.91M$4.26M$5.46M$6.82M$5.53M$6.37M$6.29M$4.85M$3.99M
    Interest Expense$203,000$212,000$222,000$231,000$244,000$249,000$232,000$235,000$226,000$194,000$211,000$218,000
    Income Before Tax$-62,766,000$-57,762,000$-35,564,000$-50,672,000$-71,349,000$-40,849,000$43.27M$-2,353,000$-17,852,000$-1,732,136$-26,148,000$-26,489,000
    Income Tax Expense$-274,000$52,000$134,000$-127,000$-1,001,000$-994,000$-1,592,000$6.22M$170,000$1.34M$211,000$218,000
    Net Income$-62,492,000$-57,814,000$-35,698,000$-50,545,000$-70,348,000$-39,855,000$44.86M$-8,570,000$-18,022,000$-3,071,977$-26,148,000$-26,489,000
    EBITDA$-59,511,297$-54,775,000$-32,173,000$-47,376,000$-68,079,000$-37,460,000$46.58M$915,000$-14,524,000$-10,528,609$-24,135,000$-24,453,634
    EBIT$-62,563,000$-57,550,000$-35,342,000$-50,441,000$-71,105,000$-40,600,000$43.50M$-2,118,000$-17,626,000$-13,560,350$-25,890,763$-26,271,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about IMTX

    News

    Immatics: 'Buy' On Anzu-Cel 1st Half 2027 Catalyst And Potential Label Expansion For Uveal Melanoma

    Immatics N.V. (IMTX) is rated "Buy" due to its lead product anzu-cel (IMA203), a PRAME-directed TCR therapy in a phase 3 trial for 2nd-line melanoma, with key data expected in H1 2027. Positive earlier data and potential expansion into metastatic uveal melanoma support the investment thesis. The company has extended its cash runway by raising $150M, but faces clinical, regulatory, and competitive risks.

    Seeking Alpha•8/25/26•
    Bullish

    Form 424B2 Immatics N.V.

    Immatics N.V. is offering 12,945,916 ordinary shares and pre-funded warrants to purchase 4,315,304 ordinary shares at a public offering price of $8.69 per ordinary share. The estimated net proceeds of $140.0 million will be used for research and development, manufacturing, and general corporate purposes. Investing in these securities carries high risk, including immediate dilution and potential Passive Foreign Investment Company (PFIC) status for U.S. investors.

    StreetInsider•8/25/26•
    Somewhat-Bullish

    Nayax, Immatics, Moderna, Marvell Technology And Other Big Stocks Moving Higher On Tuesday

    U.S. stocks saw a positive Tuesday, with the Nasdaq Composite rising and several companies experiencing significant share gains. Nayax Ltd surged after announcing the acquisition of IPS Group Inc. for $350 million, while Moderna Inc. climbed following analyst upgrades due to landmark Phase 3 oncology data. Marvell Technology Inc. also saw an increase, with analysts raising their price targets.

    Benzinga•8/25/26•
    Somewhat-Bullish

    Why is Immatics stock climbing today?

    Immatics NV (IMTX) stock rose nearly 4.7% in pre-open trading, driven by a planned $150 million public offering of shares and pre-funded warrants. Further support came from Goldman Sachs reiterating a Buy rating, following the company's strong second-quarter 2026 financial results. These factors, combined with a positive NASDAQ performance and analyst optimism, suggest renewed investor confidence in Immatics' pipeline.

    Investing.com•8/25/26•
    Bullish

    Why is Immatics stock climbing today?

    Immatics NV (IMTX) stock rose nearly 4.7% in pre-open trading after the company announced plans for a $150 million public offering of shares and pre-funded warrants. The stock also received a boost from Goldman Sachs, which reiterated its Buy rating on the shares, adding to a strong bullish analyst consensus with an average 12-month price target of $17-$19. This positive momentum, combined with an earnings beat and clinical milestones, fueled investor optimism.

    Investing.com•8/25/26•
    Neutral

    Frequently Asked Questions About IMTX

    Does IMTX pay dividends?
    Immatics NV (IMTX) does not currently pay a regular dividend.
    What is IMTX's market cap?
    Immatics NV (IMTX) has a market capitalization of $1.44B with a current stock price of $9.53.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In